Company Overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Why Investors Should Care
Trades at a P/E of 23.5, below the sector median of 25.4.
Operating margin of 19.3% supports profitability.
Offers a dividend yield of 3.10%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Apr 2026 Revenue of $36.36B (+8.4% YoY); net profit $4.80B.
- Trailing 12 Months Year-on-year growth — revenue +13.7%, earnings +40.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.2%, profit CAGR 2.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.22% |
| 1 Year: | 13.70% |
Compounded Profit Growth
| 5 Years: | 2.54% |
| 1 Year: | 40.70% |
Stock Price Performance
| 1 Year: | +6.03% |
| 6 Months: | +16.49% |
| 3 Months: | +14.22% |
| 1 Month: | +8.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.13 · Neutral
P/E of 23.50 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 3.10%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDT Medtronic plc SPXR3KPHARMA | 95.41 | 23.50 | $122.04B | 3.10% | 7.95% | 10.65% | 6.22% | 2.54% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2015 | Apr 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 7.39B | 7.05B | 7.37B | 8.14B | 7.38B | 7.48B | 7.55B | 8.15B | 7.49B | 7.71B | 7.72B | 6.00B | 6.51B | 7.65B | 7.78B | 7.99B | 7.85B | 7.76B | 7.37B | 7.58B | 7.73B | 7.70B | 7.98B | 8.09B | 7.92B | 8.40B | 8.29B | 8.58B | 8.96B | 9.02B |
| Gross Profit | 3.19B | 4.37B | 4.82B | 4.88B | 4.79B | 5.20B | 4.91B | 5.02B | 5.01B | 5.48B | 5.04B | 4.93B | 5.17B | 5.75B | 5.18B | 5.28B | 5.28B | 5.66B | 5.13B | 5.31B | 5.32B | 3.73B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 1.27B | - | 1.13B | 1.30B | 1.35B | - | 1.17B | 1.39B | 1.15B | - | 1.38B | 1.89B | 1.44B | - | 1.24B | 1.54B | 1.54B | - | 1.49B | 1.35B | 1.64B | - | 673.00M | 930.00M | 1.28B | 859.00M | 1.56B | 1.66B | 1.12B | 1.40B | 1.39B | 1.27B | 1.34B | 1.48B | 1.28B | 1.59B | 1.65B | 1.45B | 1.69B | 1.46B |
| Net Income | 977.00M | -1.00M | 820.00M | 520.00M | 1.09B | 1.10B | 929.00M | 1.11B | 821.00M | 1.16B | 1.02B | 2.02B | -1.39B | 1.46B | 1.07B | 1.11B | 1.27B | 1.17B | 864.00M | 1.36B | 1.92B | 646.00M | 487.00M | 489.00M | 1.27B | 763.00M | 1.31B | 1.48B | 929.00M | 427.00M | 1.22B | 791.00M | 909.00M | 1.32B | 1.04B | 1.27B | 1.29B | 1.04B | 1.37B | 1.14B |
| Diluted EPS | 0.98 | 0.00 | 0.57 | 0.36 | 0.77 | 0.78 | 0.66 | 0.80 | 0.59 | 0.84 | 0.74 | 1.48 | -1.03 | 1.07 | 0.79 | 0.82 | 0.94 | 0.87 | 0.64 | 1.01 | 1.42 | 0.48 | 0.36 | 0.36 | 0.94 | 0.56 | 0.97 | 1.10 | 0.70 | 0.32 | 0.92 | 0.59 | 0.68 | 0.99 | 0.80 | 0.99 | 1.01 | 0.81 | 1.07 | 0.89 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.59B | 17.00B | 20.26B | 28.83B | 29.71B | 29.95B | 30.56B | 28.91B | 30.12B | 31.69B | 31.23B | 32.36B | 33.54B | 36.36B |
| Gross Profit | - | 12.67B | 13.95B | 19.69B | 20.42B | 20.90B | - | - | - | - | - | - | - | - |
| Operating Income | 4.40B | 3.81B | 3.77B | 5.36B | 5.38B | 6.64B | 6.27B | 4.79B | 4.48B | 5.75B | 5.49B | 5.14B | 5.96B | 6.47B |
| Net Income | 3.47B | 3.06B | 2.67B | 3.54B | 4.03B | 3.10B | 4.63B | 4.79B | 3.61B | 5.04B | 3.76B | 3.68B | 4.66B | 4.80B |
| Diluted EPS | 3.37 | 3.02 | 2.41 | 2.48 | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.94B | 106.69B | 99.64B | 99.86B | 91.39B | 89.69B | 90.69B | 93.08B | 90.98B | 90.95B | 89.98B | 91.68B | 93.03B |
| Total Equity | 17.11B | 18.67B | 19.44B | 53.23B | 52.06B | 50.21B | 50.72B | 50.09B | 50.74B | 51.43B | 52.55B | 51.48B | 50.21B | 48.02B | 49.46B |
| Cash & Equivalents | 1.17B | 919.00M | 1.40B | 4.84B | 2.88B | 4.97B | 3.67B | 4.39B | 4.14B | 3.59B | 3.71B | 1.54B | 1.28B | 2.22B | 1.95B |
| Long Term Debt | - | - | - | 33.17B | 29.94B | 25.87B | 23.69B | 24.55B | 22.14B | - | - | - | - | - | - |
| Total Liabilities | - | - | 18.50B | 53.45B | 47.58B | 49.53B | 40.57B | 39.48B | 39.82B | 41.48B | 38.26B | 39.28B | 39.56B | 43.42B | 42.96B |
| Current Liabilities | - | - | 5.56B | 9.17B | 7.17B | 14.26B | 10.08B | 8.47B | 10.37B | 8.51B | 12.39B | 9.05B | 10.79B | 12.88B | 11.66B |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 4.96B | 4.90B | 5.22B | 6.88B | 4.68B | 7.01B | 7.23B | 6.24B | - | 6.04B | 6.79B | 7.04B | 7.33B |
| Investing Cash Flow | - | -3.59B | -17.06B | 2.25B | -1.57B | 5.86B | -774.00M | -3.20B | -2.87B | - | -3.49B | -2.37B | -1.94B | -2.93B |
| Financing Cash Flow | - | -918.00M | 15.95B | -9.54B | -3.28B | -11.95B | -5.43B | -4.20B | -4.14B | - | -4.96B | -4.45B | -4.36B | -4.75B |
| Capital Expenditure | -457.00M | -396.00M | -571.00M | -1.05B | -1.25B | -1.07B | -1.13B | -1.21B | -1.35B | - | -1.46B | -1.59B | -1.86B | -1.90B |
| Free Cash Flow | - | 4.56B | 4.33B | 4.17B | 5.63B | 3.62B | 5.87B | 6.02B | 4.88B | - | 4.58B | 5.20B | 5.18B | 5.43B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -2.41B | -29.00M | 746.00M | -354.00M |
| Share Buybacks | 1.25B | 2.55B | 1.92B | 2.83B | 3.54B | 2.17B | 2.88B | 1.33B | 652.00M | 2.54B | 645.00M | 2.14B | 3.23B | 1.03B |
Ratios (Annual)
Figures in %.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 74.5% | 68.9% | 68.3% | 68.7% | 69.8% | - | - | - | - | - | - | - | - |
| Operating Margin % | 26.5% | 22.4% | 18.6% | 18.6% | 18.1% | 22.2% | 20.5% | 16.6% | 14.9% | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Net Margin % | 20.9% | 18.0% | 13.2% | 12.3% | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| ROE % | 18.6% | 15.8% | 5.0% | 6.8% | 8.0% | 6.1% | 9.2% | 9.4% | 7.0% | 9.6% | 7.3% | 7.3% | 9.7% | 9.7% |
| ROCE % | - | 11.8% | 3.9% | 5.8% | 6.3% | 8.2% | 7.7% | 6.0% | 5.3% | 7.3% | 6.7% | 6.5% | 7.6% | 7.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.91% | 114.02M | $10.09B |
| 2 | Vanguard Capital Management LLC | 6.55% | 83.82M | $7.42B |
| 3 | State Street Corporation | 4.96% | 63.40M | $5.61B |
| 4 | Vanguard Portfolio Management LLC | 2.66% | 34.06M | $3.01B |
| 5 | Geode Capital Management, LLC | 2.36% | 30.19M | $2.67B |
| 6 | JPMORGAN CHASE & CO | 2.17% | 27.78M | $2.46B |
| 7 | Bank of America Corporation | 1.67% | 21.32M | $1.89B |
| 8 | Massachusetts Financial Services Co. | 1.55% | 19.87M | $1.76B |
| 9 | Morgan Stanley | 1.52% | 19.44M | $1.72B |
| 10 | Deutsche Bank AG | 1.44% | 18.45M | $1.63B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDT
Medtronic (MDT) Stock Dips While Market Gains: Key Facts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQYnozMl9KTk10Ujh3LWNTZk9ySThQR2cxajE1U2lfVTYzQ3Q4SjNSZE1RQzZ1ZllER0ZsZkhBZkFfMHVYWTdVNWNKN0FDbFdKS3ZBMGtTTkdfaG1ZQldvd2pMNGZpUFM0TlVUR3BpM0pDYXZDLTBZT2hVS2VZMFhDeUl1NDJBdzR0R2xOOT…
Medtronic (MDT) Posts Strong Ablation Data, Is The Stock Still Undervalued? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPLTZMY0NET1A0Qkg3NlpHdFhHRW9BWjJEQmVwMmlFR1BqaXRQSGhUaXNnS1RSZkFtZDF2aUxydXZCaF9PRFFLdDFWMHhrY2N5bDZSSVhBY1JUWUJ5aFI4MGlHOVZLM2ptV09VelNjWC1wRFJ1QTZ0eEJ4VUhxZGNmbTM4VGRmTExpRlcwSj…
If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock? - Trefis
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOaFg3WDd5NzR3WW1pNzVqSHRON0RpVVNTdlEwMlJ4WENjTmFoYkN0cjFUeGxRMlhYVU5MbXNvWlA2bk5HNlU2c0FwVkJRaTMyMWdWOHZPV0lDWHFyOGoyYlVBWWlGdE1iRGwtWFJYaFJfYmpCUTRhcG9DTFpsVzU0OXAtNHhlMDNnOEN0U0…
A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.1 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQZHAyY0FWNDgzdWdCRENMa3dpMEMyaVZGTmtDcHpVR0RXdGI5dml1ZjlOdDdTNjExQmFJR0NVNmNrWnNYV1VEallybEFmWTBRdWt0dlZpMU9JVzZjeThvOGxka3ZwdDlZcHdxSHFpOHR2aTRoRWpWcTRRQjZOU0puN0wwOWtiUVQtREJYRG…
Medtronic Stock Exchange Offer Explained: Discount, Key Deadlines, and Odd-Lot Rules - Barron's
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNT2RhSkVlSW1DcW9ObkZ4OUFxTjNrN1MtSW5wT193cDhRWnJ3T0ljWEtZRVhzUEprTlhnOXZDRnR5cFByTUlZSWV3cTVaN2w3eE9xODBzT2R2S3JqRnZiVzVEa29YZWdLbWszSy1Ga2V3WkJ6ZXpWUjJxM0JOZmd2VXNlMnNuNFJLZW1EY2…
Medtronic's MiniMed exchange offer oversubscribed; 18.3% acceptance - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNY3FCb19RZXhLb0l3TU5XQkxseGQxSWxHSEZaYVBMczJ5QWI2MkY1NHBMRHdoaWc2dUp0SVg5MF9paGJ3TVZXcllTcWoyeWszeVcxamRMQzQzMTJlZ1ZTNXBlUXJoVUhPc24zb1dmRXh6b3RkaEtXZHBmTXJRVmROdlg2bDVmdFBnQ3Y4c1…
MDT — Frequently Asked Questions
What is the current share price of Medtronic plc (MDT)?
As of 2026-10-23 16:27 PDT, Medtronic plc (MDT) trades at $95.41 on NYSE. Its 52-week range is $72.50 to $101.97.
What is the market capitalisation of MDT?
Medtronic plc (MDT) has a market capitalisation of $122.04B on NYSE.
What is the P/E ratio of MDT?
MDT trades at a trailing price-to-earnings (P/E) ratio of 23.50. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.35.
Does MDT pay a dividend?
Medtronic plc (MDT) currently offers a dividend yield of 3.10%.
What is the return on equity (ROE) of MDT?
MDT has a return on equity (ROE) of 10.65%. Its return on capital employed (ROCE) is 7.95%.
Is MDT a good stock to buy?
This page provides a data-driven analysis of Medtronic plc (MDT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.